ESGE Endorses Mauna Kea's Cellvizio® for Enhanced Pancreatic Cyst Diagnosis

Mauna Kea Technologies announced a significant milestone as the European Society of Gastrointestinal Endoscopy (ESGE) recommends the use of Cellvizio® for pancreatic cyst characterization. The endorsement by ESGE, a leading authority in endoscopy, positions Cellvizio® as a pivotal technology in improving diagnostic accuracy for pancreatic cysts.

The recognition emphasizes the utility of needle-based confocal laser endomicroscopy (nCLE) which provides real-time, high-resolution imaging. Studies have shown that nCLE substantially improves diagnostic accuracy compared to conventional methods, aiding in better differentiation of mucinous and non-mucinous cysts.

Data from multi-center studies reveal nCLE's diagnostic sensitivity and accuracy, notably reducing unnecessary surgeries by 23% and decreasing clinical costs by 13%. This ESGE recommendation marks a critical advancement in the adoption of nCLE, potentially influencing reimbursement and establishing Cellvizio® as a standard for pancreatic cyst diagnosis.